OncLive TV

Gina Z. D’Amato, MD, shares her interpretation of efficacy outcomes from the negative Alliance A092104 trial in advanced uterine leiomyosarcoma.

Ou Deng, PhD, discussed findings from a study investigating MSH6-modulated PARP inhibitor sensitivity in BRCA-proficient, high-grade serous ovarian cancer.

Apar Kishor Ganti, MD, discusses the importance of molecular testing in NSCLC and the profiling capabilities of the Oncomine DX Express Test.

Darren Pan, MD, highlights the novelty of anito-cel in relapsed/refractory multiple myeloma, including the difference in safety profile vs cilta-cel.

Sonam Puri, MD, discusses future research directions and ongoing developments in small cell lung cancer.

Dickon Hayne, MD, FRCS, MBBS, discusses mitomycin in combination with BCG in patients with high-risk non–muscle-invasive bladder cancer.

Alexander Chehrazi-Raffle, MD, discusses findings from an exploratory analysis of the TiNivo-2 trial of tivozanib with/without nivolumab in metastatic RCC.

Ajai Chari, MD, expands on the evolving debate surrounding transplant eligibility determination in newly diagnosed multiple myeloma.

Alicia Morgans, MD, MPH, discusses how PRO data from the ARANOTE trial could inform the selection of darolutamide plus ADT for patients with mHSPC.

Ruby Arora, MD, discusses the design of a retrospective analysis of temporal trends in MCL incidence from 2000 to 2021.

Peter Voorhees, MD, details the clinical implications of cilta-cel for the treatment of patients with relapsed/refractory multiple myeloma.

Thomas Powles, MD, MBBS, MRCP, discusses the implications of data from sasanlimab plus BCG in patients with BCG-naive, high-risk NMIBC.

Naomi B. Haas, MD, discusses safety data from the phase 3 KEYNOTE-564 trial of adjuvant pembrolizumab in patients with clear cell renal cell carcinoma.

Janice M. Mehnert, MD, discusses the efficacy and safety profile of sarilumab plus ipilimumab, nivolumab, and relatimab in unresectable melanoma.

Yair Lotan, MD, discusses guideline-supported treatment avenues for patients with BCG-unresponsive NMIBC.

Tali Azenkot, MD, discusses the rationale for combining dupilumab with cemiplimab in early-stage, resectable non–small cell lung cancer.

Hyein Jeon, MD, highlights key abstracts and takeaways from an OncLive Fellows Forum on lung cancer.

Alexander B. Olawaiye, MD, discusses data with relacorilant plus nab-paclitaxel in platinum-resistant ovarian cancer that led to the phase 3 ROSELLA trial.

Richard Finn, MD, discusses the addition of tiragolumab to atezolizumab and bevacizumab in advanced hepatocellular carcinoma.

Rocío García-Carbonero, MD, discusses a subgroup analysis of fruquintinib vs placebo in patients with refractory metastatic colorectal cancer.

Benjamin L. Schlechter, MD, discusses efficayc and safety of botensilimab in combination with the anti–PD-1 antibody balstilimab in mCRC.

Yelena Y. Janjigian, MD, discusses patient-reported outcomes and QOL assessments for durvalumab plus FLOT in resectable gastric/GEJ adenocarcinoma.

Eileen M. O’Reilly, MD, discusses the rapidly evolving role of local therapy in the management of advanced/metastatic pancreatic cancer.

Benjamin A. Weinberg, MD, FACP, discusses preliminary efficacy and safety findings from BXCL701 with pembrolizumab in microsatellite-stable mPDAC.

Qi Cheng, MD, discusses the safety and efficacy of irpagratinib plus atezolizumab in advanced hepatocellular carcinoma.

Theresa Medina, MD, discusses the long-term efficacy and safety of lifileucel TIL therapy in advanced melanoma.

Fatima Cardoso, MD, MSc, FESMO, discusses the use of elinzanetant for vasomotor symptoms in women receiving endocrine therapy for HR+ breast cancer.

David Spigel, MD, discusses the potential clinical effect of a 14-gene molecular assay for identifying candidates for adjuvant chemotherapy in NSCLC.

Naval G. Daver, MD, discusses early efficacy and safety data for bexmarilimab plus azacitidine in patients with higher-risk myelodysplastic syndrome.